Broadcast Date: October 11, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Efforts to identify biomarkers for neurodegenerative disease have been hampered by the lack of a proteomic tool with the required sensitivity to detect very low concentrations of brain-derived proteins in plasma or serum and the ability to multiplex many analytes in a single assay.

In this webinar, we will describe the NULISA Platform, a novel immunoassay with attomolar level sensitivity and high multiplex capability. The performance of the NULISA assay was benchmarked to existing immunoassay platforms and Dr. Zetterberg will present data from his evaluation of the NULISA system’s ability to detect serum biomarkers associated with Alzheimer’s disease. Dr. Henrik Zetterberg is a leading researcher in the field of Alzheimer’s disease who has spent the past 10 years focused on the discovery and validation of blood-based biomarkers for CNS disorders.


During the presentation we will offer a chance to pose questions to our expert panelists. Any questions submitted during the webinar will be answered at a later date.

Doug Hinerfeld
Doug Hinerfeld, PhD
Senior Director of Application Support
Alamar Biosciences
Henrik Zetterberg
Henrik Zetterberg, MD, PhD
Professor of Neurochemistry
University of Gothenburg


The post NULISA: Ultra-Sensitive Immunoassay Platform for Profiling Fluid-Based Neurodegenerative Protein Biomarkers appeared first on GEN – Genetic Engineering and Biotechnology News.